Warfarin: To use or not to use in chronic kidney disease patients?

Journal of Nephrology

Volumn 23, Issue 6, 2010, Pages 648-652

  Cozzolino, Mario ^a   Brandenburg, Vincent ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Chronic kidney disease; Matrix Gla protein; Vascular calcification; Vitamin K; Warfarin

Indexed keywords

COUMARIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY CALCIFICATION; BLEEDING; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG SAFETY; DRUG USE; FISTULA; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; NONHUMAN; REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT DURATION; UREMIA;

ANTICOAGULANTS; CALCIUM-BINDING PROTEINS; CHRONIC DISEASE; EXTRACELLULAR MATRIX PROTEINS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; WARFARIN;

EID: 78549259399     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Ireland R. Warfarin bleeding risk increased in CKD. Nature Rev Nephrol. 2009;5:306.
2. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009;20:912-921.
3. Cozzolino M, Brancaccio D, Gallieni M, et al. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int. 2005;68:429-436. (Pubitemid 43323098)
4. Cozzolino M, Mazzaferro S, Pugliese F, et al. Vascular calcification and uremia: what do we know? Am J Nephrol. 2008;28:339-346.
5. Krueger T, Westenfeld R, Schurgers LJ, Brandenburg VM. Coagulation meets calcification: the vitamin K system. Int J Artif Organs. 2009;32:67-74.
6. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78-81. (Pubitemid 27130923)
7. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol. 1998;18:1400-1407.
8. Schurgers LJ, Spronk HM, Soute BA, et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007;109:2823-2831.
9. Koos R, Krueger T, Westenfeld R, et al. Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost. 2009;101:706-713.
10. Koos R, Mahnken AH, Muhlenbruch G, et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol. 2005;96:747-749. (Pubitemid 41317640)
11. Schurgers LJ, Aebert H, Vermeer C, et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood. 2004;104:3231.
12. Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56:569-579. (Pubitemid 46400180)
13. Shearer MJ. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care. 2000;3:433-438.
14. Zebboudj AF, Shin V, Bostrom K. Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem. 2003;90:756-765. (Pubitemid 37392466)
15. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15:2857-2867.
16. Schurgers LJ, Teunissen KJ, Knapen MH, et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol. 2005;25:1629-1633.
17. Cranenburg EC, Brandenburg VM, Vermeer C, et al. Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost. 2009;101:359-366.
18. Cozzolino M. Matrix-Gla protein and vascular calcification: the negative role of oral anticoagulant therapy. Thromb Haemost. 2009;101:605-606.
19. Hermann S-M, Whatling C, Brand E, et al. Polymorphisms of the human matrix Gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20:2386-2393.
20. Brancaccio D, Biondi ML, Gallieni M, et al. Matrix gla protein gene polymorphisms and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol. 2005;25:548-552. (Pubitemid 41816049)
21. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol. 2009;20:872-881.
22. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305-1316.
23. Nakatani T, Naganuma T, Uchida J, et al. Asymptomatic occlusive lesions of cerebral arteries in Japanese hemodialysis patients. Artif Organs. 2003;27:281-284. (Pubitemid 36423487)
24. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2009;20:705-711.